Biotech Values

[CT]

I think it's likely they get approved but that expectation is mostly in the stock already. So one of those "more downside than upside" events.

(No position in the stock - I did own it and did nicely, but in retrospect sold quite a bit too soon).

It seems like the clinical data is solid, Xifaxan has an endorsement from the ACG already, and is already approved for another indication.

Is the IBS market (non-IBS-C population) so small that it won't add meaningfully to the bottom line? Is reimbursement a problem with a drug like this? Or is it the indication?

Traders are definitely taking bets against SLXP in the short term via options. The OI numbers for Mar puts are huge compared to Mar calls.

Maybe the game is the same as ever except now everyone sells before the expected news :)